Cue Biopharma (CUE) announced the appointment of Patrick Verheyen to its board of directors, BOD. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson (JNJ). Verheyen had a distinguished 35-year career with Janssen Pharmaceutical Companies of Johnson & Johnson where he held positions of growing responsibility until his retirement as Global Head, Janssen Business Development in 2021.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CUE:
- Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
- 2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
- Cue Biopharma price target lowered to $8 from $9 at Stifel
- Cue Biopharma reports Q4 EPS (37c) vs (26c) last year
- Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
